ADPT
Adaptive Biotechnologies CorporationHealthcare · $4.6B market cap
Verdict
We can't put a fair value on ADPT right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.
Business quality
1 of 5 clear the 10% bar. What are the Big Five?
Follow ADPT
Track it on your watchlist and see the full analysis. Free.
Create a free accountSuperinvestors
2 of the investors we track hold ADPT. In Q2 2026, 1 trimmed. Who we track
Viking Global Investors
Viking Global Investors · as of Q2 2026
$643.4M
29,993,708 shares
Polen Capital Management
Polen Capital Management · as of Q2 2026
$2.2M
102,457 shares
Moves in Q2 2026
Trimmed: Polen Capital Management
Insider activity
Since Aug 31, 2026: no open-market purchases and 1 other filing (stock awards, tax withholding and similar). Why purchases matter
Other filings
About Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corporation, founded in 2009 and headquartered in Seattle, Washington (operating as Adaptive TCR Corporation until its name change in December 2011), is a commercial-stage entity focused on pioneering an immune medicine platform. This advanced platform is engineered for the precise diagnosis and effective treatment of a broad spectrum of illnesses. The company offers several core…
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works